news
Two companies, Neurimmune and Ethris, will leverage their technologies to…
6 April 2020 | By Hannah Balfour (Drug Target Review)
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.